Antacids may increase the appearance of white opaque substance in Helicobacter pylori-eradicated gastric epithelial neoplasia

Abstract

Background and study aims White opaque substance (WOS) in gastric epithelial neoplasia is helpful for qualitative diagnosis of neoplasia. We hypothesized that WOS of neoplasia is strongly influenced by acid recovery after Helicobacter pylori eradication, similar to that of gastric intestinal metaplasia. The aim of this study was to investigate whether antacids increase the appearance of the WOS in H. pylori-eradicated neoplasia.

Patients and methods A total of 38 gastric epithelial neoplasias (12 adenomas and 26 adenocarcinomas) detected after H. pylori eradication were retrospectively evaluated. Presence or absence of WOS was evaluated by magnifying endoscopy with narrow band imaging before and after antacid administration. The pH of collected gastric juice was also measured. Study endpoints were (1) prevalence of WOS in the neoplasia before and after antacid administration, and the histological difference (adenoma and adenocarcinoma); and (2) relationship between the prevalence of WOS and gastric juice pH.

Results WOS prevalence increased from 0 % (0/38) to 44.8% (17/38) after antacid administration. WOS prevalence in adenomas was more significantly increased compared to that in adenocarcinomas (83.3 % vs 26.9 %, P = 0.0077). Prevalence of WOS in gastric neoplasias was only observed at neutral levels of gastric juice pH, and WOS was not observed at strong acidic levels.

Conclusions Antacid administration may increase the appearance of WOS in gastric epithelial neoplasia (especially adenomas) detected after H. pylori eradication with acid recovery.

• References

• 1 Yao K, Iwashita A, Tanabe H. et al. White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma. Gastrointest Endosc 2008; 68: 574-580
• 2 Yao K, Iwashita A, Nambu M. et al. Nature of white opaque substance in gastric epithelial neoplasia as visualized by magnifying endoscopy with narrow-band imaging. Dig Endosc 2012 24: 419-425
• 3 Ueo T, Yonemasu H, Yada N. et al. White opaque substance represents an intracytoplasmic accumulation of lipid droplets: Immunohistochemical and immunoelectron microscopic investigation of 26 cases. Dig Endosc 2013; 25: 147-155
• 4 Ueo T, Yonemasu H, Yao K. et al. Histologic differentiation and mucin phenotype in white opaque substance-positive gastric neoplasia. Endosc Int Open 2015; 3 : E597-E604
• 5 Ohtsu K, Yao K, Matsunaga K. et al. Lipid is absorbed in the stomach by epithelial neoplasms (adenomas and early cancers): a novel functional endoscopy technique. Endosc Int Open 2015; 3: E318-E322
• 6 Rubin W, Ross LL, Jeffries GH. et al. Some physiologic properties of heterotopic intestinal epithelium. Its role in transporting lipid into the gastric mucosa. Lab Invest 1967; 16: 813-827
• 7 Siurala M, Tarpila S. Absorptive function of intestinal metaplasia of the stomach. Scand J Gastroenterol 1968; 3: 76-79
• 8 Ueo T, Wada K, Murakami K. Clinical significance of the white opaque substance positive intestinal metaplasia evaluated by H.pylori status. J Gastroenterol Hepatol 2017; 32 (Suppl. 03) 93
• 9 Togo K, Ueo T, Yao K. et al. White opaque substance visualized by magnifying narrow-band imaging is associated with intragastric acid conditions. Endosc Int Open 2018; 6: E830-E837
• 10 Borgstrom B, Brockman HL. Lipases. Amsterdam: Elsevier; 1984
• 11 Taguchi Y, Kaito M, Gabazza EC. et al. Helicobacter pylori inhibits the secretory activity of gastric parietal cells in patients with chronic gastritis. An ultrastructural study. Scand J Gastroenterol 1997; 32: 656-663
• 12 Kato S, Matsukura N, Matsuda N. et al. Normalization of pH level and gastric mucosa after eradication of H.pylori in the remnant stomach. J Gastroenterol Hepatol 2008; 23: 258-261
• 13 Segawa K, Nakazawa S, Tsukamoto Y. et al. Estimate of gastric acid output by evaluation of fasting gastric juice collected endoscopically. Hepatogastroenterology 1991; 38: 79-82
• 14 Kobayashi M, Hashimoto S, Nishikura K. et al. magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol 2013; 48: 1332-1342
• 15 Ito M, Tanaka S, Takata S. et al. Morphological changes in human gastric tumors after eradication therapy of Helicobacter pylori in a short-term follow up. Aliment Pharmacol 2005; 21: 559-566
• 16 Ueo T, Yonemasu H, Wada K. Attempt to improve qualitative diagnosis by administration of PPI to gastric adenoma detected after H.pylori eradication. Journal of Japanese Society of Gastroenterology 2017; 114: A252 (in Japanese)
• 17 Gotoda T, Saito D, Kondo H. et al. Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. J Gastroenterol 1999; 34: 91-96
• 18 Hori Y, Imanishi A, Matsukawa J. et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-238
• 19 Sakurai Y, Mori Y, Okamoto H. et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg orrabeprazole 10 mg in healthy adult male subjects--a randomised open-labelcross-over study. Aliment Pharmacol Ther 2015; 42: 719-730